Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary
November 2, 2023
Earnings Call Speaker Segments
Ed Berg
executiveGood afternoon, everyone, and thanks for being here on today's call. Joining us from Vaxart are our Chief Executive Officer, Andrei Floroiu; Dr. James Cummings, our Chief Medical Officer; Phillip Lee, our Chief Financial Officer; and Brant Biehn, Senior Vice President of Business Operations. Before we begin, I'd like to remind everyone that during this conference call, Vaxart may make forward-looking statements. Those include statements about the company's financial results, financial guidance, future business strategies and operations, and product development and regulatory progress, including statements regarding its ongoing or planned clinical trials. The outcomes we ultimately report may end up substantially different from what these forward-looking statements describe, and that's due to several significant elements — among them the unpredictability that's simply part of clinical development and the regulatory pathway, plus the additional risks laid out under the Risk Factors heading in Vaxart's latest annual report on Form 10-K, as well as in its other periodic filings with the SEC. Vaxart has no duty to revise any forward-looking statements once this call has taken place. At this point I'll hand things over to Andre Floroiu. Andre?
Cezar Floroiu
executiveThanks, Ed, and I appreciate everyone being here today. On this call, we're going to walk through the clinical advances we've recently achieved with our norovirus program, which got autocorrected there. We'll also give you a view of the milestones we have planned, and touch briefly on our COVID program, and then we'll take your questions. In Q3, we made significant strides in confirming the strength of our mucosal vaccine platform. We put out positive top line results from 2 Phase II studies in the norovirus program. The first came from our Phase II dose-ranging trial of the bivalent oral norovirus vaccine candidate, and the second came from our Phase II norovirus challenge study. What we learned from these 2 trials will shape where this program goes next, and in our view, it could reshape both the way norovirus is perceived and the vaccination paradigm itself, as you're aware. James will walk through the scientific details from these trials more thoroughly. But before that, I want to share a handful of key takeaways from what we've learned so far in this norovirus program. Number one: our oral field vaccine candidate could lower rates of norovirus infection, acute gastroenteritis, and viral shedding. Those were the central findings from the challenge study we recently ran. Our belief is that when shedding is substantially reduced, transmission is slowed dramatically. That's a remarkable potential advantage of these vaccines. Number two: in our view, these data confirm the promise of our oral tablet norovirus vaccine program. To date, we've finished 8 clinical trials in norovirus, and every one of them demonstrated that our vaccines produce strong immune responses and are safe and well tolerated, with no serious adverse events tied to the vaccine. We have confidence in the Vaxart platform and in many of our programs as we work toward a registrational Phase III study. And number three: we think we've now established clinical proof of concept for our oral field platform through 2 human challenge studies — one in norovirus, the other in influenza. In both instances, we showed that our oral field vaccine technology has a clear and consistent effect on several important measures, including lowering the rate of infection, illness, and shedding. Our view remains that we have the most advanced norovirus vaccine candidate in clinical development, one that is both formulated for oral administration and designed to be delivered to the gastrointestinal system. A pill vaccine could genuinely transform how we invest in this globally, how vaccines are made, how they're distributed, and how we are ministerial. Not to mention that far more people would take vaccines that aren't mill-based, while more and more regions of the world could gain access to an oral pill that doesn't carry the coaching and infrastructure demands of injectables. I want to underscore the impact of the disease we're up against. At a joint expert meeting on microbiological risk assessment held in Rome, Italy by the Food and Agriculture Organization and the World Health Organization, norovirus was just designated the top cause of foodborne illness in adults. On top of that, norovirus ranks first as a cause of gastroenteritis; in the U.S. by itself, this disease carries an economic burden surpassing $10 billion each year, and worldwide it exceeds $60 billion. The burden of norovirus infections falls disproportionately on young children and the elderly. Not long ago, in the clinical trial we announced earlier, we gave a dose to the first participant, testing whether our norovirus vaccine candidate can produce antibodies in breast milk and pass those antibodies along to young infants. This study's potential excites us, since an oral norovirus vaccine field may allow mothers to shield their infants from this extremely contagious disease, which brings serious health consequences. Now, a quick update on our COVID-19 program. We keep moving forward on a possible COVID vaccine, and we think cross reactivity in our present construct points to a pathway toward a pan coronavirus vaccine. A number of recent forecasts predict new COVID variants will keep emerging, worsening how long this serious public health threat persists. Because we have made the norovirus program our priority, we are evaluating next steps for the COVID program, and those could involve several options. Once we settle on the way forward for this important program, we look forward to sharing the information. I'll now hand the call to James, who will review recent progress on our norovirus program.
James Cummings
executiveThanks, Andre. During Q3, our norovirus program achieved significant clinical progress, and we announced topline results from two distinct Phase II studies; for this vaccine candidate and for our overall vaccine platform, we feel the data reported so far looks encouraging. Now I want to give you a concise overview of the two studies. Let me begin with findings from the Phase II dose-ranging trial of the bivalent norovirus vaccine candidate. As you may remember, this candidate includes two genotypes, G11 and G24, and over roughly the last two decades, both have been responsible for most norovirus illness in people. Safety and immunogenicity served as the primary endpoints, so that a dose level could be selected for Phase III development. Early data from the trial showed robust cellular immune activity in the CRM at day 29 compared with day 1 at all dose levels. A similar increase in antibody levels in the blood occurred with both vaccine doses, and no statistically meaningful gap emerged between the medium and high dose groups. On Page 29, among those who received the vaccine, for the G24 and G11 strains alike, the jumps in serum IgA, serum IgG and BT50 looked much like what had been seen in prior Vaxart norovirus trials. What's more, these results indicate the bivalent norovirus vaccine candidate had good tolerability, with a favorable safety profile showing no serious adverse events, or SAEs, tied to the vaccine and no dose-limiting toxicity. Across both doses, the rate of adverse events was on par with placebo. Let's move on to the Phase II G11 norovirus challenge trial. That study looked at how safe, how immunogenic, and how effective our monovalent norovirus vaccine candidate is. We had two main goals. First, we wanted to show clinical efficacy — that is, whether our monovalent norovirus vaccine candidate, compared with placebo, protects people against norovirus acute gastroenteritis, or AGE, brought on by the Norwalk Strain challenge inoculum. Second, we wanted to measure the VP1 specific IgA antibody secreting cells, or ASCs, along with the HPGA blocking antibody, plus the VP1 specific serum IgA and serum IgG responses to the vaccine. This was a double-blinded, randomized, placebo-controlled study. Healthy volunteers either got a single oral dose of our norovirus vaccine candidate aimed at the G11 strain of norovirus, or they got placebo on day 1. During days 29 and 30, the people taking part were exposed to the G1 strain of norovirus, after which they were checked for infection, norovirus AGE, and immune responses up to day 57. Five of the study's 6 primary endpoints were achieved. According to the findings, there was a 29% relative drop in infection that reached statistical significance. In the vaccinated group versus placebo, there was a 21% relative decrease in norovirus AGE that did not reach statistical significance, along with an 85% relative decrease in viral shedding, which was a prespecified study endpoint. During the data announcement, we mentioned that we think these findings bolster the possibility that our neurovirus vaccine initiative could deliver substantial public health advantages. We also consider these to be key results that back the prospective application of our oral pill vaccine platform and help make a norovirus vaccine possible. As I mentioned before, the first subject has now been given a dose in our Phase I trial. That study is evaluating Vaxart's oral tablet bivalent norovirus vaccine candidate, and it focuses on safety and immunogenicity, along with lactating mothers. This represents a significant milestone in Vaxart's effort to develop a vaccine that might reduce the severe global health threat posed by norovirus, especially for children under 5 years old. Roughly 21 million individuals in the United States fall ill from norovirus every year, and 15% of children younger than age 5 get norovirus each year. We think an oral tablet norovirus vaccine could allow others to shield their infants from this extremely contagious virus. Regarding what comes next for the norovirus program, we are still running further analyses on data from our earlier norovirus trials, and those analyses will guide our decisions about how to proceed. On the registration side, what comes next is a Phase IIb trial to confirm the dose for our bivalent candidate, which will let us collect sufficient safety information to back an end of Phase II meeting with the FDA here in the United States; that meeting with the FDA remains on track for the end of 2024. At this point I'll hand things over to Phil Lee, our Chief Financial Officer, for a brief rundown of our financials. Phil, the floor is yours.
Phil Eric Lee
executiveThanks, James. Today's press release lays out the specifics of how we did financially in the third quarter of 2023. Our revenue came in at $2.1 million for the third quarter of 2023, whereas we recorded no revenue at all in the third quarter of 2022. Most of that $2.1 million in revenue during the third quarter of 2023 came from funds we recognized for work carried out under the Vaxart scrap contract from the Bill and Melinda Gates Foundation. As of the close of the third quarter of 2023, Vaxart held cash, cash equivalents, restricted cash and marketable securities totaling $53 million, down from $67.9 million on June 30, 2023. That drop largely reflects the cash we spent on operations while moving our programs forward. We still expect our existing cash to carry us into the third quarter of 2024. I appreciate everyone taking the time today; at this point we'll open things up for your questions.
Mayank Mamtani
analystCould I ask a few clarifying questions about the correlate of protection and the additional analysis that's underway? Maybe you could share any color you have there. Also, are you examining both the monovalent and bivalent data sets for the core protection? And is that needed for the Phase IIb dose confirmation study?
James Cummings
executiveThanks. James Cummings here. I'll handle those. Regarding correlative protection, that analysis from our challenge study is ongoing. As you might remember, the challenge study involved a monovalent vaccine against a matched monovalent strain of challenge inoculum. As we said, we're confident a correlate of protection will be established, and that work continues. As for which data sets are being used, we would definitely turn to the challenge study to identify that correlate of protection. We will definitely examine other studies and past analyses to determine where that correlate sits; however, at this time the correlate's determination rests on the challenge study. Then, how that could affect a Phase IIb or, more importantly, a Phase III study would depend on dialogue with the FDA. Although we hope to garner additional safety data from a Phase II study of Phase IIb to bring us to an end of Phase II meeting with the FDA, which is, as I mentioned, still online for still on schedule for end of 2024.
Liang Cheng
analystLeon here, sitting in for Roger. We've got a few questions for you. First off, I'd like to ask about the possible Phase II or Phase IIb trial. Could you give us any details regarding how that study would be designed — specifically the enrollment size, the timing, and so on?
James Cummings
executiveJames here. I'll handle that one. Some of the additional analyses we're running could have a certain effect on how the Phase IIb study gets designed, though the purpose will be to strengthen the total patient numbers as we head toward an end of Phase II meeting with the FDA. With that in mind, the figure would land somewhere around at least 400 or so, possibly a greater number of people who've been given test article, and then proceeding from there. That study would provide the direct assessment of safety and immunogenicity.
Liang Cheng
analystSo here's another thing I recall — I believe I brought up that you might run an additional challenge study, something in the ballpark of 5 billion. What's the thinking on that right now?
James Cummings
executiveSure. At present, the norovirus G11 strain challenge has been completed and reported on, and I'm eager to share that further analysis with the community; once we're in dialogue with the FDA, we'll decide whether to proceed with that correlate to impact the Phase III study design; and should it be needed, another challenge study using G24 could be carried out; however, right now, it isn't a requirement. Were it to be carried out, it could run in parallel with a Phase IIb study. We'll know more about that after the correlate has been identified and those initial discussions with the FDA have taken place.
Liang Cheng
analystUnderstood. Perhaps a brief follow-up regarding how the Phase I trial was structured. You brought up how transmission reduction gets measured going into Phase III, and why that matters, so has the agency given any response on that transmission reduction piece?
James Cummings
executiveWhat we previously disclosed was a substantial drop in viral shedding, and our belief is that this could translate into less transmission when public health policy standards are applied. Having said that, the only information we possess concerns viral shedding, and that finding is statistically significant, showing an 84% relative reduction. Those findings would subsequently be collected further within a Phase III trial.
Brant Biehn
executiveThanks a lot, operator. We have received quite a few questions from different places — our shareholders and other folks who are interested. Several of them deal with norovirus. I believe some have already been addressed. There was definitely significant curiosity about the correlative protection as well as the timing of a Phase III trial for norovirus, though I think James has already taken care of those. Here's one I'd like to direct to you, James, seeking a bit more clarity on norovirus; the question reads, could you give us an update regarding where things stand with your analysis of the additional noro data recently — it continues into a path forward toward a Phase IIb trial; however, I'd say the timeline for additional oral data matters most in this context. Shortly.
James Cummings
executiveRight now, we are assessing additional immune response information, along with data at the level of each individual subject in that trial. We are eager to provide those specifics for the analysis once it is finished.
Brant Biehn
executiveThanks, James. The next one is aimed at you, and it's really about where this organization is headed. The specific thing being asked is whether there are any plans during 2024 to bring forward new product candidates... Andre?
Cezar Floroiu
executiveThanks, Brant. Now, when we turn our attention toward 2024, what we'll keep concentrating on is figuring out the strongest paths forward for the clinical pipeline we already have, which at this point consists of—as a lot of you are aware—the norovirus program, the pan coronavirus program, and the flu program. And our view is that pursuing this would generate well beyond a sufficient number of catalysts and chances to build value for an organization of the scale we operate at.
Brant Biehn
executiveThanks, Andre. All right. Several inquiries have come in regarding our financial position. Phil, this next one is directed at you. To be specific, the person is asking whether you plan to start the Phase IIb trial using the cash we currently have, or if more capital will have to be brought in to cover the cost of that trial, Phil?
Phil Eric Lee
executiveTo sum things up, right now we're running further analyses on the results from our norovirus studies, and as soon as we've figured out which direction the program will take, we'll share news about what comes next. In doing so, should it make sense, we might also refresh the guidance on how long our cash will last. All right, thanks, Phil.
Brant Biehn
executiveSwitching over to the clinical side, and James, this relates to the study involving lactating mothers; so the inquiry regarding the lactating mother study is, when do you expect to have top line data.
James Cummings
executiveAppreciate it. As we get nearer to completing enrollment, we'll have a clearer idea of when data from this study will arrive. So far, that study has 7 subjects enrolled.
Brant Biehn
executiveGreat, and I have one more thing to ask about that too, James — could you walk us through again where the locating mother study data sits within the broader development program for the norovirus Canada?
James Cummings
executiveVaccinating mothers who are breastfeeding could therefore boost the norovirus ediaglobulins present in their milk, and that might assist in shielding the baby who nurses. And this is — this is genuinely one element of our approach aimed at safeguarding this at-risk group.
Brant Biehn
executiveGreat. There's plenty of interest in this topic. So Indresen, you're asking about more money coming in from outside parties, in particular BARDA or other U.S. government bodies that oversee such things; let me put the question to you, and it's been raised in many different forms. Is there anything new you can share regarding Project NextGen funding? And is it still possible for you to get money from BARDA or NIH for this program? Andre?
Cezar Floroiu
executiveRight, so if there were something concrete to tell you, we'd pass it along — and there isn't. Even so, our optimism hasn't changed. Our position is the same one we've expressed on many occasions: that the U.S. government should back our pan coronavirus program. When we look at which programs got money under the NextGen program, our view stays the same — ours deserves backing, since it offers a number of possible benefits that set it apart from those other programs. So, to repeat, we hold to that view: if the U.S. hopes to make a major gain in its capacity to handle future dynamics, backing for our program is warranted. And the moment we have anything specific to report, you'll hear it from us.
Brant Biehn
executiveOkay. Thank you, Andre. James, here's one more for you. Let's return to the World Vaccine Congress. So the question is this: is there anything new from the World Vaccine Congress that you're able to share, James?
James Cummings
executiveAbsolutely, thank you. The information we gathered from the norovirus challenge study got a really positive response. And when people compared that with how our candidate vaccine could perform against natural infection, that stood out too. The crucial point is that natural infection usually comes from being exposed to somewhere between 10 and 100 virus particles. Keep in mind that the challenge inoculum contained 1 million virus particles. So our belief is that the overall level of protection during a natural infection will probably be greater, since the amount of virus to defend against is much smaller.
Brant Biehn
executiveGreat, thanks a lot. Phil, I've got one more question on the finance side about the GATE study. So what I'd like to ask you, Phil, is this: what amount of revenue tied to the GATE study has yet to be recognized, and across what period will that happen? Phil?
Phil Eric Lee
executiveAbsolutely. Thank you, Brant. We record grant revenue during the span in which the corresponding expenses are generated and services are delivered. As things stand now, we have actually recorded nearly all of the existing grant money from the Bill & Melinda Gates Foundation. Right now, my expectation is that we will recognize the $79,000 that is left during 2023's fourth quarter.
Brant Biehn
executiveExcellent. Thank you, Phil. Okay. And operator, that closes our Q&A.
Operator
operatorIn that case, feel free to hang up now, and enjoy the rest of your day. We appreciate you joining us today.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.